Abstract: The latest advances on target therapies of cancer were presented on the 44th Annual Meeting of American Society of Clinical Oncology(ASCO)in 2008.One of the most important results was the outstanding efficacy of Cetuximab in Metastatic Colorectal Cancer fIncao patients with k-ras"wild-type".Besides,detection of k-ras statuswouldmakeitpossibleforthetailoredtargettherapy of mCRC.Itwasestimatedthat k-ras gene status would become a predictive molecular marker for Cetuximab treatment in mCRC.